Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. | Aplastic Anemia and MDS International Foundation

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.

Journal Title: 
Haematologica
Author(s): 
Kim SY, Le-Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ
Primary Author: 
Kim SY
Original Publication Date: 
Friday, August 8, 2014

A proportion of patients with aplastic anemia who are treated with immunosuppressive therapy develop clonal hematologic disorders, including myelodysplastic syndrome (post-aplastic anemia myelodysplastic syndrome). Many will proceed to allogeneic hematopoietic stem cell transplantation. We identified 123 patients with post-aplastic anemia myelodysplastic syndrome who from 1991 through 2011 underwent allogeneic transplantation, and in a matched-pair analysis compared outcomes to that in 393 patients with de novo myelodysplastic syndrome. There was no difference in overall survival. There were no significant differences in regards to 5-year probabilities of relapse, non-relapse mortality, relapse-free and overall survival which were 14%, 40%, 46% and 49% for post-aplastic anemia myelodysplastic syndrome, and 20%, 33%, 47% and 49% for de novo myelodysplastic syndrome, respectively. Cytogenetic risk was independently associated with overall survival in both groups. Thus, transplant success in patients with post-aplastic anemia myelodysplastic syndrome was similar to that in patients with de novo myelodysplastic syndrome, and cytogenetic risk was the only significant prognostic factor for post-aplastic anemia myelodysplastic syndrome patients.

Bone Marrow Diseases: